SOURCE: Nutex Health, Inc. or prnewswire.com
Nutex Health Chairman and CEO Tom Vo to Speak on Panel at Upcoming Danaher Summit on Diagnostics
HOUSTON, Nov. 1, 2023 /PRNewswire/ — Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced that Thomas Vo, M.D., MBA, Founder, Chairman and CEO will be a panelist speaker at the Danaher Summit on Diagnostics: Insights to Impact on November 7, in Washington, D.C.
Nutex Health Speaker Details:
Date: Tuesday, November 7, 2023
Time: 1:30 PM ET
Venue: The Ritz Carlton
Address: 1150 22nd Street Northwest, Washington, D.C. 20037
Dr. Vo will be speaking on Panel 4, “Diagnostic Insights to Impact: The Hospital Director/Healthcare Systems.” He will be accompanied by Dr. Michael Zinner, CEO and Executive Medical Director at Miami Cancer Institute, and Dr. T. Clifford Deveny, President and CEO of Summa Health.
About Nutex Health Inc.
Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.
The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 22 facilities in 8 states.
The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups. Our cloud-based proprietary technology platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers, allowing us to deliver greater quality care more efficiently.
Forward-Looking Statements
Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-Q for the period ended March 31, 2023 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.
SOURCE Nutex Health, Inc.
DANAHER SUMMIT ON DIAGNOSTICS: INSIGHTS TO IMPACT
NOVEMBER 7, 2023
7:15 AM-8:00 PM ET
The Ritz-Carlton
1150 22nd Street Northwest
Washington, D.C. 20037
SPEAKERS
AGENDA
ACCOMMODATIONS
REGISTER
The second annual Danaher Summit will focus on critical challenges that the diagnostics industry faces in unlocking the promise of precision medicine. This invitation-only, private event is a unique venue where conversations will put a strong emphasis on initiating actionable outcomes and fostering a culture of collaboration among stakeholders. We will bring together an interdisciplinary world-class team of over 250 leading experts, united by a sense of urgency and a call to action to sustainably scale and implement multimodal precision diagnostics, a cornerstone of precision medicine.
Programming will include keynote speeches from Dr. Stephen Hahn, Dr. Atul Butte, and Lord Ara Darzi, as well as panels of luminaries discussing diagnostics through five key lenses: the patient, the provider, the payer, the hospital director, and the innovator.
CONFIRMED SPEAKERS
Stephen Hahn
MD
CEO
Harbinger Health
Atul Butte
MD, PhD
Priscilla Chan and Mark Zuckerberg Distinguished Professor
UCSF
Ara Darzi of Denham
OM, KBE, PC, FRS, MD
Institute of Global Health Innovation (IGHI)
Imperial College London
Maimah Karmo
Patient/Survivor, President and CEO
Tigerlily Foundation
Gary Puckrein
PhD
President and CEO
National Minority Quality Forum
Loriana Hernandez Aldama
Patient/Survivor, Founder
ArmorUp for LIFE
Cecilia Schott
PharmD, MBA
VP, Head of Global Precision Diagnostics
Novartis
Scott Friedman
MD
Professor of Pharmacologic Sciences, Chief, Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
Lincoln Nadauld
MD, PhD
President and CEO
Culmination Bio, Inc.
Adam Myers
MD, MHCM, FACHE, CHCQM, CPHRM
Former Chief Clinical Transformation Officer
Blue Cross Blue Shield
Jill Hagenkord
MD, FCAP
Chief Medical Officer
Optum Genomics
T. Clifford Deveny
MD
President and CEO
Summa Health
Lee Fleisher
MD
Former Chief Medical Officer
Centers for Medicare and Medicaid Services
David Walt
PhD
Hansjörg Wyss Professor of Biologically Inspired Engineering
Harvard Medical School
Andy Beck
MD, PhD
CEO
PathAI
Shai Shen-Orr
PhD
Assoc. Prof. at the Technion – Israel Institute of Technology, Founder & Chief Scientist, CytoReason
Anthony Philippakis
MD, PhD
Chief Data Officer
Broad Institute
Mara Aspinall
MBA
Partner
Illumina Ventures
Jeremiah Hinson
MD, PhD
CMO, Associate Professor of Emergency Medicine
StoCastic (acquired by Beckman Coulter Diagnostics), JHU School of Medicine
Rob Monroe
MD, PhD
VP and CSO Oncology, CMO
Danaher Diagnostics, Leica Biosystems
Zivjena Vucetic
MD, PhD
SVP and CMO
Beckman Coulter Diagnostics
Kemi Badaki-Makun
MD, PhD
Director of Research for the Division of Pediatric Emergency Medicine
Johns Hopkins School of Medicine
Michael Zinner
MD
CEO and Executive Medical Director
Miami Cancer Institute
Tom Vo
MD, MBA
CEO
Nutex Health
Paul D. Banick
MD, PhD, MBA
CEO and Chief Medical Officer
Dynamic Health Results, PLLC
Bill Morice
MD, PhD
President and CEO
Mayo Collaborative Services
Julian Knight
Professor of Genomic Medicine
University of Oxford
Jonathan Siegrist
PhD
Chief Technology Officer
Cepheid
PRELIMINARY AGENDA
November 7, 2023
7:15 AM ET
Registration and Breakfast
8:00 AM ET
Welcoming Remarks
8:05 AM ET
Opening Remarks
8:20 AM ET
Keynote Presentation
Stephen Hahn
CEO
Harbinger Health
9:00 AM ET
Panel 1: Diagnostic Insights to Impact: The Patient
Gary Puckrein
President and CEO
National Minority Quality Forum
Loriana Hernandez Aldama
Patient/Survivor, Founder
ArmorUp for LIFE
9:45 AM ET
Panel 2: Diagnostic Insights to Impact: The Provider
Scott Friedman
Professor of Pharmacologic Sciences, Chief, Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
Lincoln Nadauld
President and CEO
Culmination Bio, Inc.
10:30 AM ET
Break and Networking
11:00 AM ET
Panel 3: Diagnostic Insights to Impact: The Payer
Adam Myers
Former Chief Clinical Transformation Officer
Blue Cross Blue Shield
Jill Hagenkord
Chief Medical Officer
Optum Genomics
11:45 AM ET
Keynote Presentation
Atul Butte
Priscilla Chan and Mark Zuckerberg Distinguished Professor
UCSF
12:25 PM ET
Lunch and Networking
1:25 PM ET
Panel 4: Diagnostic Insights to Impact: The Hospital Director / Healthcare System
Michael Zinner
CEO and Executive Medical Director
Miami Cancer Institute
T. Clifford Deveny
President and CEO
Summa Health
2:10 PM ET
Lightning Presentations
Zivjena Vucetic
SVP and CMO
Beckman Coulter Diagnostics
Jeremiah Hinson
CMO, Associate Professor of Emergency Medicine
StoCastic (acquired by Beckman Coulter Diagnostics), JHU School of Medicine
3:50 PM ET
Break and Networking
4:05 PM ET
Panel 5: Diagnostic Insights to Impact: The Innovator
David Walt
Hansjörg Wyss Professor of Biologically Inspired Engineering
Harvard Medical School
Andy Beck
CEO
PathAI
4:50 PM ET
Keynote Presentation
Ara Darzi of Denham
Institute of Global Health Innovation (IGHI)
Imperial College London
5:30 PM ET
Closing Remarks
6:00 PM ET
Cocktail Reception
ACCOMMODATIONS
A limited number of rooms at the Ritz-Carlton are available at a special conference rate.
Please indicate in your registration form if you are interested.
Other recommended hotels include:
The Fairmont
2401 M Street Northwest
Washington, D.C. 20037
The Park Hyatt
1201 24th Street Northwest
Washington, D.C. 20037
Marriott Georgetown
1221 22nd Street Northwest
Washington, D.C. 20037
REGISTRATION
REGISTER NOW
https://www.prnewswire.com/news-releases/nutex-health-chairman-and-ceo-tom-vo-to-speak-on-panel-at-upcoming-danaher-summit-on-diagnostics-301973574.html
